Page 146 - 80 guidelines for the treatment of malaria_opt

nd
Guidelines for the treatment of malaria – 2 edition

a6.7 references

1. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic
resistance. Proceedings of the National Academy of Sciences of the USA, 1997, 94:12106–
12111.
2. Lipsitch M, Levin BR. The population dynamics of antimicrobial chemotherapy.
Antimicrobial Agents and Chemotherapy, 1997, 41:363–373.
3. Austin DJ, Anderson RM. Studies of antibiotic resistance within the patient, hospitals and
the community using simple mathematical models. Philosophical Transactions of the Royal
Society of London, Series B, Biological Sciences, 1999, 354:721–738.
4. Peters W. Chemotherapy and drug resistance in malaria, 2nd ed. London, Academic Press,
1987.
5. White NJ. Antimalarial drug resistance and combination chemotherapy. Philosophical
Transactions of the Royal Society of London, Series B, Biological Sciences, 1999, 354:739–
749.
6. Jeffery GM, Eyles DE. Infectivity to mosquitoes of Plasmodium falciparum as related to
gametocyte density and duration of infection. American Journal of Tropical Medicine and
Hygiene, 1955, 4:781–789.
7. Mackinnon MJ, Hastings IM. The evolution of multiple drug resistance in malaria parasites.
Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92:188–195.
8. Hastings IM, Mackinnon MJ. The emergence of drug-resistant malaria. Parasitology, 1998,
117:411–417.
9. Roper C et al. Intercontinental spread of pyrimethamine-resistant malaria. Science, 2004,
305:1124.
10. Dye C, Williams BG. Multigenic drug resistance among inbred malaria parasites.
Proceedings of the Royal Society of London, Series B, Biological Sciences, 1997, 264:61–67.
11. White NJ. Antimalarial pharmacokinetics and treatment regimens. British Journal of
Clinical Pharmacology, 1992, 34:1–10.
12. White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics of
artemether-lumefantrine. Clinical Pharmacokinetics, 1999, 37:105–125.
13. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with
pyrimethamine-sulphadoxine: selective pressure for resistance is a function of long
elimination half-life. Transactions of the Royal Society of Tropical Medicine and Hygiene,
1973, 87:75–78.
14. Nzila AM et al. Molecular evidence of greater selective pressure for drug resistance exerted
by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting
chlorproguanil/dapsone on Kenyan Plasmodium falciparum. Journal of Infectious Diseases,
2000, 181:2023–2028.
15. Hastings I, Watkins WM, White NJ. The evolution of drug-resistance in malaria: the role
of the terminal elimination half-life. Philosophical Transactions of the Royal Society of
London, Series B, Biological Sciences, 2002, 357:505–519.

132